



Biotech Daily

Thursday September 8, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: NEUREN UP 17%, FACTOR THERA DOWN 8%**
- * **NEW JERSEY'S CERTARA ACQUIRES MELBOURNE'S D3 MEDICINE**
- * **ANATARA PIGLET SAFETY STUDY READIES DETACH APPLICATION**
- * **OPTISCAN RIGHTS ISSUE RAISES \$550k, TOTAL \$2.2m**
- * **BIO-MELBOURNE SEPTEMBER BIO-BRIEFING TAKES A RISK**

MARKET REPORT

The Australian stock market fell 0.71 percent on Thursday September 8, 2016 with the ASX200 down 38.4 points to 5,385.8 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 16 fell, six traded unchanged and one was untraded.

Neuren was the best, up 0.7 cents or 17.1 percent to 4.8 cents with 987,664 shares traded.

Dimerix climbed 7.1 percent; Orthocell was up 6.15 percent; Airxpanders improved five percent; Anteo, Cellmid, Living Cell and Viralytics were up more than three percent; Avita, Ellex, IDT and Opthea rose more than two percent; Pharmaxis and Universal Biosensors were up more than one percent; with Clinuvel, CSL, Nanosonics and Reva up by less than one percent.

Factor Therapeutics led the falls, down 0.4 cents or 7.8 percent to 4.7 cents with 267,020 shares traded.

Uscom lost 5.2 percent; Cyclopharm fell 4.2 percent; Actinogen and Admedus were down more than three percent; Mesoblast and Osprey shed more than two percent; Acrux, Bionomics, Genetic Signatures and Psivida were down more than one percent; with Cochlear, Compumedics, Impedimed, Medical Developments, Pro Medicus, Resmed and Sirtex down by less than one percent.

D3 MEDICINE

D3 says it has been acquired by the Princeton, New Jersey-based Certara, with the value of the transaction undisclosed.

The privately-owned Melbourne-based D3 previously said it was a bio-pharmaceutical strategic advisory company, providing planning and stewardship of drug development programs, with former Roche and CSL executive Dr Craig Rayner as chief executive officer and former Biota and GBS Venture Partners executive Dr Leigh Farrell as chief operating officer (BD: Jul 2, Oct 9, 2014; Nov 23, 24, 2015).

Today D3 said that Certara was a “provider of decision support technology and consulting services for optimizing drug development and improving health outcomes” and its 13 staff would become part of Certara’s strategic consulting division, which was formed in July 2015 through the merger of Quantitative Solutions and Pharsight Consulting Services. D3 said that Certara’s strategic consulting division was “the largest consultancy of its kind ... [with] more than 100 scientists ... using a broad range of modelling and simulation methods and technologies to support global sponsors in bringing new therapies to patients”.

Certara chief executive officer Dr Edmundo Muniz said that the acquisition of D3 strengthened his company’s “ability to provide our clients with optimized and strategic drug development plans”.

“Our shared mission is to revolutionize the drug development paradigm by applying quantitative science and technologies in an integrated manner to inform the most crucial drug development decisions,” Dr Muniz said.

“Certara has helped sponsors bring more than 80 new drugs to market, including more than 40 percent of the novel drugs approved by the US Food and Drug Administration last year,” Dr Muniz said.

ANATARA LIFESCIENCES

Anatara says its Detach “pivotal target animal safety study” to control diarrhoea in piglets” has shown the pineapple-stem bromelain-based compound is safe.

Anatara said that the dossier for Detach registration with the Australian Pesticides and Veterinary Medicines Authority was being prepared for submission by October 2016 for an Australian launch in 2017.

The company said that the study’s objective was “to provide detailed safety data on Detach when administered to piglets at dose rates higher and more frequent than the recommended dose ... in the case of accidental overdosing, or repeated administration”.

Anatara said the study of 40 piglets showed that Detach was safe when administered orally at the recommended dose rate of 2.0mL and also at 6.0mL and 10mL and Detach was dosed on six occasions from two days after birth to 18 days of age, a frequency “which far exceeds the recommended dosing regimen”.

The company said there were no differences between placebo-control piglets in any of the parameters studied, including body weight gain, tissue weights, tissue histopathology examination, haematology, serum chemistry, and urine analysis.

Anatara chief scientific officer Dr Tracey Mynott said that the “studies complete the clinical trials component of the ... dossier”.

The company said that the only outstanding item to complete the dossier application was a validation report from its manufacturing partner, which was part of the chemistry and manufacturing requirements and was a procedural matter.

Anatara was unchanged at \$1.20.

OPTISCAN

Optiscan says it has completed its \$2.16 million capital raising with \$750,000 from its placement \$550,000 from the rights Issue and \$860,000 from the underwriters.

Optiscan said it was “well-funded to continue to drive [its] strategic direction”.

The company said that the funds would help drive commercialization of the Celllive microscopy product, development and commercialization of a flexible probe and the second generation rigid probe system and complete and launch the Carl Zeiss collaboration project.

Optiscan fell 0.1 cents or 3.3 percent to 2.9 cents.

BIO-MELBOURNE NETWORK

The Bio-Melbourne Network says its September 13, 2016 Bio-Briefing will discuss corporate culture and risk.

Bio-Melbourne Network chief executive officer Dr Krystal Evans said “companies working in the biotechnology and medical technology sectors all take on risk in order to achieve their business objectives against the backdrop of a constantly changing regulatory and commercial environment”.

Dr Evans said that building a strong organizational culture was a key part of the approach to risk management, both in terms of preventing bad outcomes and to actively empower the positive risk-taking necessary for successful innovation.

The Network said that speakers and the panel would discuss approaches to tackling risk as an opportunity and how to empower people to make better decisions in the context of a changing healthcare landscape.

The Bio-Melbourne Network said that PKF Australia partner Ken Weldin would address the briefing will be followed by a panel discussion with Governance Matters managing-director Kate Costello, Anatomics’ chief executive officer Andrew Batty and IDT Australia chief financial officer and company secretary Joanna Johnson.

The Network said that directors, chief executive officers, chief financial officers and senior decision-makers with an interest in organizational culture and risk management would find the session highly relevant.

The Bio-Melbourne Network said that the Bio-Briefing would be held at The Cube at the Australian Centre for the Moving Image, Federation Square, Melbourne, with registration from 4:00pm and the presentation and panel discuss from 4pm to 5.15pm followed by a networking session.

To register go to: <http://bit.do/biobriefingcultureandrisk>.